




## Supplementary Figures and Table




**Figure S1.** Cell viability of EPCs treated with various concentrations of SR-1 for 24 h and 48 h as measured by CCK cell viability assay. The data are presented as mean  $\pm$  standard deviation. (\*\* $p < 0.01$  and \*\*\* $p < 0.001$  vs. control)




**Figure S2.** Morphology of SR-1(1 μM)-treated EPCs (scale bar, 400 μm). The boxed regions are shown at a high magnification ( $\times 2$ ) in the inset.




**Figure S3.** Flow cytometry analysis of cell surface markers of EPC (CD34, c-Kit, CXCR4, VEGFR-2, and CD144) in controls or SR-1-treated EPCs.




**Figure S4.** Cell viability of EPCs treated with various concentrations of FICZ for 48 h as measured by CCK cell viability assay. (n.s represents no significance, \* $p < 0.05$  and \*\* $p < 0.01$  vs. control)




**Figure S5.** Morphology of FICZ (100 nM)-treated EPCs (scale bar, 400  $\mu\text{m}$ ). The boxed regions are shown at a high magnification ( $\times 2$ ) in the inset.




**Figure S6.** CYP1A1 mRNA levels were examined using qRT-PCR. The mRNA levels were normalized to GAPDH. (\*\*\*) $p < 0.001$  vs. control, FICZ 100 nM treatment)




**Figure S7.** (A) Flow cytometry analysis was used for cellular ROS measurement using H<sub>2</sub>DCFDA dye in young and senescent EPCs. (B) Percentages in the representative histograms indicate the accumulated ROS levels. (\*p<0.05 and \*\*\*p<0.001 vs. control, FICZ 100 nM treatment)



**Figure S8.** (A) Representative phase-contrast images for long-term culture of EPCs with continuous FICZ or SR-1 treatment (Scale bar, 400 μm). (B) The boxed regions are shown at a high magnification (×2) in the inset. Cell morphometric parameters measuring cell area. (\*p<0.05 and \*\*p<0.01 vs. control, FICZ 100 nM and SR-1 1 μM treatment)



**Figure S9.** (A) SA-β-gal activity was measured in FICZ or SR-1-continuously treated EPCs (Scale bar, 200 μm). (B) Percentage of SA-β-gal+ cells. (\*p<0.05 and \*\*\*p<0.001 vs. control, FICZ 100 nM and SR-1 1 μM treatment)



**Figure S10.** (A) H<sub>2</sub>DCFDA (green) fluorescence representative images in EPCs with continuous FICZ or SR-1 treatment. The nucleus was stained by Hoechst-33342 (Blue) (Scale bar, 200  $\mu$ m). (B) The quantified data of H<sub>2</sub>DCFDA fluorescence intensity. The data are presented as mean  $\pm$  standard deviation. (\* $p$ <0.05 and \*\* $p$ <0.01 vs. control, FICZ 100 nM and SR-1 1  $\mu$ M treatment)

**Table S1. Primer sequence for quantitative RT-PCR**

Gene	Primer	sequences
<i>AhR</i>	Forward	5'- CTTCCAAGCGGCATAGAGAC -3'
	Reverse	5'- AGTTATCCTGGCCTCCGTTT -3'
<i>CYP1A1</i>	Forward	5'- CTTGGACCTCTTTGGAGCTG -3'
	Reverse	5'- CGAAGGAAGAGTGTCGGAAG -3'
<i>CYP1A2</i>	Forward	5'- CAATCAGGTGGTGGTGTCTCAG -3'
	Reverse	5'- GCTCCTGGACTGTTTTCTGC -3'
<i>CYP1B1</i>	Forward	5'- TGTCTGGCCTTCCTTTATG -3'
	Reverse	5'- TCATCACTCTGCTGGTCAGG -3'
<i>IL-6</i>	Forward	5'- TACCCCCAGGAGAAGATTCC -3'
	Reverse	5'- TTTTCTGCCAGTGCCTCTTT -3'
<i>IL-1<math>\alpha</math></i>	Forward	5'- AATGACGCCCTCAATCAAAG -3'
	Reverse	5'- TGGGTATCTCAGGCATCTCC -3'
<i>Ang1</i>	Forward	5'- AAATGGAAGGAAAACACAAGGAA -3'
	Reverse	5'- ATCTGCACAGTCTCTAAATGGT -3'
<i>bFGF</i>	Forward	5'- TTCCTTCATAGCCAGGTAACGG -3'
	Reverse	5'- ATCTGCACAGTCTCTAAATGGT -3'
<i>IL-8</i>	Forward	5'- GTGCAGTTTTGCCAAGGAGT -3'

---

	Reverse	5'- CTCTGCACCCAGTTTTCCTT -3'
<i>GAPDH</i>	Forward	5'- ACCACAGTCCATGCCATCAC -3'
	Reverse	5'- TCCACCACCCTGTTGCTGTA -3'

---